News for MARVEL BIOSCIENCES CORP (MRVL.V)

Marvel Biosciences (TSXV: MRVL) successfully raised $1,018,750 through a private placement. 8,150,000 units were issued, each priced at $0.125 and consi

MB-204 significantly outperformed Trofinetide in treating Rett syndrome, showing sustained effects up to three weeks post-treatment. The study revealed

\n Marvel Biosciences (TSXV: MRVL, OTCQB: MBCOF) to present at IRSF Scientific Meeting in June 2025. Company to discuss promising preclinical data on MB-20

Marvel Biosciences (TSXV: MRVL) (OTCQB: MBCOF) to present Alzheimer's research at AAIC 2025. Preclinical data shows MB-204 reduces tau hyperphosphorylat

February 28, 2025 (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces today's roundup of stocks added ...

Marvel Biosciences Corp.  and its wholly owned subsidiary, Marvel Biotechnology Inc. , is pleased to announce a collaboration with Professor Emmanuel Planel of Laval University to study the acute...

Calgary, Alberta - January 6, 2023 (Newsfile Corp.) (Investorideas.com Newswire) Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel B...

/PRNewswire/ -- FinancialNewsMedia.com News Commentary - Anti-anxiety drugs are medications that are used to treat anxiety disorders that are mainly used to...

Calgary, Alberta - December 16, 2021 (Newsfile Corp.) (Investorideas.com Newswire) Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel...